Key result
First-line Navelbine and doxorubicin achieves a 74% objective response rate in advanced breast cancer.
Why the study?
Does the combination of vinorelbine and doxorubicin improve objective response rates in women with advanced or metastatic breast cancer?
Does the combination of vinorelbine and doxorubicin improve objective response rates in women with advanced or metastatic breast cancer?
The combination of vinorelbine and doxorubicin demonstrates an encouraging 74% objective response rate as first-line therapy for advanced breast cancer, though it is associated with significant neutropenia and some cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Supports evaluation of vinorelbine-doxorubicin; leaves open comparative efficacy versus standards in advanced breast cancer.
PURPOSE: The study investigated the therapeutic effects of a combination of Navelbine (vinorelbine or 5'noranhydrovinblastine; Pierre Fabre Médicament, Boulogne, France) and doxorubicin in women who had received no prior chemotherapy for locally advanced or metastatic breast cancer. PATIENTS AND METHODS: Ninety-seven patients with progressive and assessable advanced or metastatic breast cancer who had received no prior chemotherapy except in an adjuvant setting were entered onto the study. Eighty-nine patients were assessable for toxicity and response by World Health Organization (WHO) criteria; the other eight patients were excluded because they did not meet entry criteria or because of protocol violations. Navelbine was administered at 25 mg/m2 by 30-minute intravenous (IV) infusion on days 1 and 8, and doxorubicin at 50 mg/m2 by slow IV infusion on day 1, with each course repeated at 3-week intervals. Patients were treated for a maximum of 11 cycles or until progression or major toxicity. RESULTS: Objective responses were observed in 66 of 89 assessable patients (74%; 95% confidence interval, 63% to 85%). There were nineteen (21%) complete responses (CRs) and 47 (53%) partial responses (PRs). In addition, 20 patients (22.5%) had stable disease and three (3.5%) progressed while on treatment. Responses were observed at all sites of metastatic disease. Forty-one of 58 patients with visceral disease responded (71%) and 25 of 31 with soft tissue and bone disease experienced an objective response (81%). The median duration of response was 12 months (range, 2.4 to 40.5), and the median overall survival was 27.5 months (range, 4 to 46). Neutropenia was dose-limiting, with 36 patients (41%) experiencing grade 3 or 4 toxicity. Of 727 cycles administered, there were 20 admissions (3%) for treatment of febrile neutropenia, involving 14 of 89 patients (16%). Treatment-related cardiotoxicity at grade 2 to 4 was experienced by 10% of patients and necessitated the interruption of treatment in 1.5% of cycles. Other side effects were uncommon or manageable by conventional means. CONCLUSION: The encouraging response rates and duration achieved with this combination of Navelbine/doxorubicin under the conditions of this study deserve further randomized comparative trials with standard regimens.
No takes yet. Share an insight, caveat, or question.
Spielmann et al. (1994) studied locally advanced or metastatic breast cancer (n=97). Navelbine (vinorelbine) and doxorubicin was evaluated on Objective response (95% CI 63% to 85%). First-line therapy with Navelbine and doxorubicin in women with advanced breast cancer achieved an objective response rate of 74%, with a median response duration of 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: